Innate Pharma (IPH.PA ): Launch of IND-Enabling Studies for IPH4102
11/8/2013 9:38:29 AM
MARSEILLE, France, Nov. 8, 2013 (GLOBE NEWSWIRE) -- Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, announced today that it had selected and qualified the IPH4102 drug candidate for further development.
Help employers find you! Check out all the jobs and post your resume.
comments powered by